Results from the first prospective trial of systemic treatment for von Hippel-Lindau (VHL) disease show that the antiangiogenic agent pazopanib (Votrient, Novartis) could offer a "realistic option" to surgical resection in patients with this rare, inherited cancer syndrome.
This blog is focused on providing people who have been diagnosed with either a rare cancer or with more than one cancer a place where they can keep up with information, research and discoveries that could impact their lives in the near term.
Rare cancers and multiple cancers have been ignored for too long. Research dollars are far too limited.
Please let us know if you hear of anything new that needs to be shared with our community.
